PIK3CA and cancer: We also apply these results in post-screening analysis to identify novel synthetic lethal partners of PIK3CA, which were consistently detected in both of the datasets, as well as confirmed by our CRISPR/Cas9 experiments, thereby demonstrating a direct clinical application towards improved mapping of functional vulnerabilities and genetic dependencies in cancer cells.